Literature DB >> 19550064

Montelukast induced acute hepatocellular liver injury.

A Harugeri1, G Parthasarathi, J Sharma, G A D'Souza, M Ramesh.   

Abstract

A 46-year-old male with uncontrolled asthma on inhaled albuterol and formoterol with budesonide was commenced on montelukast. He developed abdominal pain and jaundice 48 days after initiating montelukast therapy. His liver tests showed an increase in serum total bilirubin, conjugated bilirubin, aspartate aminotransferase, alanine aminotransferase, and alkaline phosphatase. The patient was evaluated for possible non-drug related liver injury. Montelukast was discontinued suspecting montelukast induced hepatocellular liver injury. Liver tests began to improve and returned to normal 55 days after drug cessation. Causality of this adverse drug reaction by the Council for International Organizations of Medical Sciences or Roussel Uclaf Causality Assessment Method (CIOMS or RUCAM) and Naranjo's algorithm was 'probable'. Liver tests should be monitored in patients receiving montelukast and any early signs of liver injury should be investigated with a high index of suspicion for drug induced liver injury.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19550064     DOI: 10.4103/0022-3859.52850

Source DB:  PubMed          Journal:  J Postgrad Med        ISSN: 0022-3859            Impact factor:   1.476


  2 in total

1.  Hepatotoxicity caused by montelukast in a paediatric patient.

Authors:  Dariusz M Lebensztejn; Anna Bobrus-Chociej; Monika Kłusek; Miroslawa Uscinowicz; Joanna Lotowska; Maria Sobaniec-Lotowska; Maciej Kaczmarski
Journal:  Prz Gastroenterol       Date:  2014-05-05

Review 2.  RUCAM in Drug and Herb Induced Liver Injury: The Update.

Authors:  Gaby Danan; Rolf Teschke
Journal:  Int J Mol Sci       Date:  2015-12-24       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.